Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenola… Read more
Concord Biotech Limited (CONCORDBIO) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.96 Billion INR
Based on the latest financial reports, Concord Biotech Limited (CONCORDBIO) has total liabilities worth ₹1.96 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Concord Biotech Limited - Total Liabilities Trend (2020–2025)
This chart illustrates how Concord Biotech Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Concord Biotech Limited Competitors by Total Liabilities
The table below lists competitors of Concord Biotech Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canaan Inc
NASDAQ:CAN
|
USA | $165.52 Million |
|
PetroChina Jinhong Energy Investment Co Ltd
SHE:000669
|
China | CN¥2.32 Billion |
|
TELUS International
NYSE:TIXT
|
USA | $2.75 Billion |
|
Peugeot Invest Société anonyme
PINK:SFFFF
|
USA | $1.19 Billion |
|
Guizhou Gas Group Corporation Ltd Class A
SHG:600903
|
China | CN¥7.33 Billion |
|
Shenke Slide Bearing Corp
SHE:002633
|
China | CN¥222.22 Million |
|
Pentamaster Corporation Bhd
KLSE:7160
|
Malaysia | RM195.33 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Concord Biotech Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Concord Biotech Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Concord Biotech Limited (2020–2025)
The table below shows the annual total liabilities of Concord Biotech Limited from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹2.22 Billion | +27.27% |
| 2024-03-31 | ₹1.74 Billion | -22.29% |
| 2023-03-31 | ₹2.24 Billion | +6.88% |
| 2022-03-31 | ₹2.10 Billion | +14.41% |
| 2021-03-31 | ₹1.83 Billion | +7.57% |
| 2020-03-31 | ₹1.70 Billion | -- |